Sanofi: Poised for Double-Digit Growth and a Strong Buy Recommendation

Stifel Nicolaus analyst Eric Le Berrigaud has maintained their bullish stance on SNYNF stock, giving a Buy rating on July 2.

Eric Le Berrigaud has given his Buy rating due to a combination of factors including Sanofi’s potential for significant growth and a robust pipeline poised to deliver. The pharmaceutical giant’s outlook for 2025 and beyond suggests a turn towards double-digit growth, which positions the company as an attractive investment for a turnaround story. Le Berrigaud anticipates that upcoming data from key trials, such as tolebrutinib’s GEMINI and HERCULES, could serve as major catalysts, enhancing Sanofi’s investment appeal and justifying its placement as a top pick for the third quarter among large-cap pharma stocks.

Despite a weaker performance at the beginning of the year, partly attributed to a profit warning and increased R&D expenses, Sanofi is expected to improve in the latter half of 2024. Le Berrigaud points to a more favorable comparison base, cost-saving initiatives impacting the P&L, and the growing contributions from new drugs like Dupixent, Altuviiio, and particularly Beyfortus. Beyfortus stands out as a potential game-changer, not only for Sanofi’s Vaccines division but also for the company’s overall revenue trajectory, with the ability to surpass the €10 billion revenue target by 2030. The combination of these elements suggests a brighter financial future for Sanofi, warranting the Buy rating.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Sanofi (SNYNF) Company Description:

Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.